Biosyent (RX) Given a C$10.00 Price Target by Raymond James Analysts

Biosyent (CVE:RX) received a C$10.00 price objective from Raymond James in a research note issued to investors on Wednesday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price target would suggest a potential upside of 23.30% from the company’s previous close.

Biosyent stock traded up C$0.19 during mid-day trading on Wednesday, hitting C$8.11. 7,458 shares of the stock were exchanged, compared to its average volume of 11,243. The firm has a market cap of $111.81 million and a price-to-earnings ratio of 20.79. Biosyent has a 12 month low of C$6.52 and a 12 month high of C$10.26.

Biosyent (CVE:RX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported C$0.11 EPS for the quarter, hitting the consensus estimate of C$0.11. The company had revenue of C$5.91 million for the quarter, compared to analyst estimates of C$6.40 million. Equities research analysts expect that Biosyent will post 0.5 EPS for the current fiscal year.

About Biosyent

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Featured Article: Portfolio Manager

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with's FREE daily email newsletter.